CRXT: Clarus Therapeutics Holdings, Inc. - Summary | Jitta

Clarus Therapeutics Holdings, Inc.

NASDAQ:CRXT

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.00
Loss Chance
58.0%
1.39JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (20)
Recent Business Performance (36)
Financial Strength (26)
Return to Shareholders (13)
Competitive Advantage (35)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 219.64% in the last year
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
1.39
100.00%
3.14
96.79%
3.07
427.55%
Pharmaceuticals
5.30
74.93%
2.27
55.12%
6.23
5.56%
COMPANY DESCRIPTION
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.